Annual report pursuant to Section 13 and 15(d)

Combined and Consolidated Statements of Stockholders' Equity

v3.20.2
Combined and Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Series A Preferred Stock [Member]
Roivant Sciences Ltd. (RSL) [Member]
Common stock [Member]
Common stock subscribed
Additional paid-in- capital
Additional paid-in- capital
Roivant Sciences Ltd. (RSL) [Member]
Net parent investment
Accumulated other comprehensive (loss) income
Accumulated deficit
Beginning Balance at Mar. 31, 2018 [1] $ (1,497)             $ (1,658) [2] $ 161  
Net transfers from parent [1],[2] 5,419             5,419    
Common stock subscription, shares [1]       4,890,662            
Foreign currency translation adjustments [1] 35               35  
Net loss [1] (4,368)             (4,368) [2]    
Ending Balance at Jul. 06, 2018 [1] (411)             (607) [2] 196  
Ending Balance,Shares at Jul. 06, 2018 [1]       4,890,662            
Beginning Balance at Mar. 31, 2018 [1] (1,497)             (1,658) [2] 161  
Net loss (28,599)                  
Ending Balance at Mar. 31, 2019 7,339 [3]     $ 4 [1] $ (3) [1] $ 31,830 [1]     346 [1] $ (24,838) [1]
Ending Balance,Shares at Mar. 31, 2019 [1]       38,590,381            
Beginning Balance at Jul. 06, 2018 [1] (411)             (607) [2] 196  
Common stock subscription [1]       $ 3 (3)          
Common stock subscription, shares [1]       31,789,305            
Issuance of common shares, net [1] 14,747     $ 1   14,746        
Issuance of common shares, net, shares [1]       1,910,414            
Transfer to Accumulated Deficit [1]               $ 607 [2]   (607)
Cash contribution [1] 13,901         13,901        
Capital contribution - stock-based compensation [1] 922         922        
Capital contribution - expenses allocated from Roivant Sciences Ltd. [1]     $ 2,230       $ 2,230      
Stock-based compensation [1] 31         31        
Foreign currency translation adjustments [1] 150               150  
Net loss [1] (24,231)                 (24,231)
Ending Balance at Mar. 31, 2019 7,339 [3]     $ 4 [1] (3) [1] 31,830 [1]     346 [1] (24,838) [1]
Ending Balance,Shares at Mar. 31, 2019 [1]       38,590,381            
Settlement of common share subscription [1] 1       $ 3 (2)        
Conversion of convertible promissory notes [1] 35,587         35,587        
Conversion of convertible promissory notes, shares [1]       3,499,995            
Issuance of preferred and common stock, net of deferred offering costs upon Business Combination and Recapitalization [1] 109,772     $ 1   109,771        
Issuance of preferred and common stock, net of deferred offering costs upon Business Combination and Recapitalization, shares [1]   10,000   12,565,000            
Capital contribution - stock-based compensation [1] 175         175        
Capital contribution - expenses allocated from Roivant Sciences Ltd. [1]     $ 1,157       $ 1,157      
Stock-based compensation [1] 6,788         6,788        
Foreign currency translation adjustments [1] (362)               (362)  
Net loss [1] (66,388)                 (66,388)
Ending Balance at Mar. 31, 2020 $ 94,069 [3]     $ 5 [1]   $ 185,306 [1]     $ (16) [1] $ (91,226) [1]
Ending Balance,Shares at Mar. 31, 2020 [1]   10,000   54,655,376            
[1] Retroactively restated for reverse recapitalization as described in Note 1.
[2] Prior to formation of the Company, Roivant Sciences Ltd. was the Company’s parent with 100% ownership interest (See Note 2[A]).
[3] Retroactively restated for the reverse recapitalization as described in Note 1.